Coronavirus (COVID-19) Vaccine Pipeline Assessment 2020 Reveals Lucrative Opportunities

February 22, 2021


According to the latest research report titled ‘Coronavirus (COVID 19) Vaccine Pipeline Assessment 2020’, available with Market Study Report LLC, worldwide coronavirus vaccine industry valuation is projected to shoot up in the forthcoming years.
 

With immense interest, industry analysts present a comprehensive documentation on coronavirus (COVID-19) vaccine pipeline analysis to enable the readers to understand the prevailing dynamics in the market and highlights the growth catalysts and challenges influencing the growth matrix.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2616877/
 

The report provides information about the coronavirus, the associated pathogens and their characteristics, while accounting the overall journey from discovery of the virus, its rapid across the globe, and efforts taken by various governments to curb its transmission. It further entails the impact on the global economy. Insights about the total detected, cured, and deaths recorded for laboratory-confirmed coronavirus cases across various regions and globally are presented.
 

The study incorporates the historic R&D for development of vaccines against SARS-CoV and MERS-CoV, meanwhile expounding on the inflowing funding for COVID-19 vaccine development. It offers insights about sponsor name, research phase, recruitments for clinical trials, and trial status.
 

Moving on, the business intelligence report enlists the major vaccine developers worldwide, and elucidates their business profile, product & service portfolio, and tactics undertaken by them to stay ahead in their vaccine development endeavor. Details about promising vaccines under clinical development and their status, for each company, are also encompassed.
 

Key contenders profiled in coronavirus (COVID-19) vaccine pipeline assessment 2020 report are University of Pittsburgh, BIOCAD, Sinovac/Dynavax, Imophoron Ltd./University of Bristol, Curevac, BioNet Asia, IAVI/Batavia Biosciences, VIDO-InterVac/University of Saskatchewan/International Vaccine Institute, Tonix Pharmaceuticals/Southern Research, iBio Inc./CC-Pharming Ltd./Infectious Disease Research Institute, AJ Vaccines, Vaxil Bio Therapeutics, Generex Biotechnology/EpiVax, Flow Pharma Inc., ExpreS2ion Biotechnologies ApS, Greffex, Codagenix/Serum Institute of India, Takis Biotech/Applied DNA Sciences/Evvivax, Zydus Cadila, Arcturus Therapeutics/Duke-NUS, Cobra Biologics/Karolinska Institute, BioNTech/Pfizer/Fosun Pharma, CanSino Biological Inc/Beijing Institute of Biotechnology, GeoVax/BravoVax, Medicago, Altimmune, Vaxart Inc., Sanofi Pasteur/Translate Bio Inc., Novavax, Moderna/NIAID, Sanofi Pasteur/GlaxoSmithKline (GSK), Janssen Pharmaceutical, Heat Biologics Inc./University of Miami, University of Oxford, Immunomic Therapeutics/EpiVax/PharmaJet, Inovio Pharmaceuticals Inc., and Clover Biopharmaceuticals/Dynavax/GlaxoSmithKline.

Chat with us